JP2023519140A5 - - Google Patents

Info

Publication number
JP2023519140A5
JP2023519140A5 JP2022552336A JP2022552336A JP2023519140A5 JP 2023519140 A5 JP2023519140 A5 JP 2023519140A5 JP 2022552336 A JP2022552336 A JP 2022552336A JP 2022552336 A JP2022552336 A JP 2022552336A JP 2023519140 A5 JP2023519140 A5 JP 2023519140A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
double
stranded
inhibitory rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022552336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519140A (ja
Filing date
Publication date
Priority claimed from GBGB2003756.0A external-priority patent/GB202003756D0/en
Priority claimed from GBGB2010276.0A external-priority patent/GB202010276D0/en
Priority claimed from GBGB2013998.6A external-priority patent/GB202013998D0/en
Priority claimed from GBGB2020553.0A external-priority patent/GB202020553D0/en
Application filed filed Critical
Priority claimed from PCT/EP2021/056540 external-priority patent/WO2021185765A1/en
Publication of JP2023519140A publication Critical patent/JP2023519140A/ja
Publication of JP2023519140A5 publication Critical patent/JP2023519140A5/ja
Ceased legal-status Critical Current

Links

JP2022552336A 2020-03-16 2021-03-15 Ｐｃｓｋ９のアンタゴニスト Ceased JP2023519140A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB2003756.0A GB202003756D0 (en) 2020-03-16 2020-03-16 Antagonist of PCSK9
GB2003756.0 2020-03-16
GBGB2010276.0A GB202010276D0 (en) 2020-07-03 2020-07-03 PCSK9 antagonist
GB2010276.0 2020-07-03
GBGB2013998.6A GB202013998D0 (en) 2020-09-07 2020-09-07 Antagonist of pcsk9
GB2013998.6 2020-09-07
GB2020553.0 2020-12-23
GBGB2020553.0A GB202020553D0 (en) 2020-12-23 2020-12-23 Antagonist of pcsk9
PCT/EP2021/056540 WO2021185765A1 (en) 2020-03-16 2021-03-15 Antagonist of pcsk9

Publications (2)

Publication Number Publication Date
JP2023519140A JP2023519140A (ja) 2023-05-10
JP2023519140A5 true JP2023519140A5 (enExample) 2024-03-15

Family

ID=75111564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552336A Ceased JP2023519140A (ja) 2020-03-16 2021-03-15 Ｐｃｓｋ９のアンタゴニスト

Country Status (7)

Country Link
US (1) US20230183694A1 (enExample)
EP (1) EP4081642A1 (enExample)
JP (1) JP2023519140A (enExample)
CN (1) CN115066498A (enExample)
CA (1) CA3167849A1 (enExample)
GB (1) GB2594788B (enExample)
WO (1) WO2021185765A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
US20250304966A1 (en) * 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
EP4402263A2 (en) * 2021-09-14 2024-07-24 Argonaute Rna Limited Treatment of cardiovascular disease
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease
CN117106781B (zh) * 2023-10-16 2024-03-22 深圳市茵冠生物科技有限公司 修饰的核酸及其产品和应用
CN117210468B (zh) * 2023-11-06 2024-02-20 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用
CN117384907B (zh) * 2023-12-11 2024-03-29 上海鼎新基因科技有限公司 抑制PCSK9表达的siRNA分子及其应用
CN121511305A (zh) * 2024-06-07 2026-02-10 迈威(上海)生物科技股份有限公司 一种抑制PCSK9基因表达的RNAi制剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004261002A (ja) * 2003-01-08 2004-09-24 Tsutomu Suzuki ｓｉＲＮＡの製造方法
WO2006125977A2 (en) * 2005-05-25 2006-11-30 The University Of York Hybrid interfering rna
CN101484588B (zh) * 2006-05-11 2013-11-06 阿尔尼拉姆医药品有限公司 抑制pcsk9基因表达的组合物和方法
CN200950065Y (zh) 2006-05-24 2007-09-19 王锦峰 一种半自动夹板装置
CA2658183A1 (en) 2006-07-17 2008-01-24 Sirna Therapeutics Inc. Rna interference mediated inhibition of proprotein convertase subtilisin kexin 9 (pcsk9) gene expression using short interfering nucleic acid (sina)
BRPI0907008A2 (pt) 2008-01-31 2015-07-07 Alnylam Pharmaceuticals Inc Métodos otimizados para liberação de dsrna alvejando o gene pcsk9
WO2009114475A2 (en) * 2008-03-09 2009-09-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
US9493774B2 (en) * 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
AU2010260148A1 (en) * 2009-06-15 2012-02-02 Alnylam Pharmaceuticals, Inc. Lipid formulated dsRNA targeting the PCSK9 gene
WO2011028938A1 (en) * 2009-09-02 2011-03-10 Alnylam Pharmaceuticals, Inc. Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
EP2562257A4 (en) * 2010-04-19 2014-10-01 Riken PROCESS FOR STABILIZING FUNCTIONAL NUCLEIC ACIDS
CA2816321A1 (en) * 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
AU2014300981B2 (en) * 2013-06-27 2017-08-10 Ricc A/S Antisense oligomers and conjugates targeting PCSK9
MX2018002158A (es) 2015-08-25 2018-07-06 Alnylam Pharmaceuticals Inc Mí‰TODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9).
KR20240067272A (ko) 2016-10-18 2024-05-16 노파르티스 아게 전구 단백질 전환효소 섭틸리신 켁신 9 (pcsk9) 단백질 감소를 통한 심혈관 사건의 예방 방법
CN109957565B (zh) * 2017-12-26 2023-04-07 广州市锐博生物科技有限公司 一种修饰的siRNA分子及其应用
WO2019126990A1 (zh) * 2017-12-26 2019-07-04 广州市锐博生物科技有限公司 一种抑制PCSK9基因表达的siRNA分子及其应用
CN117210468B (zh) * 2023-11-06 2024-02-20 北京悦康科创医药科技股份有限公司 靶向调控PCSK9基因表达的siRNA及其应用

Similar Documents

Publication Publication Date Title
Kaur et al. Thermodynamic, counterion, and hydration effects for the incorporation of locked nucleic acid nucleotides into DNA duplexes
RU2487716C2 (ru) Новые структуры малых интерферирующих рнк (sirna)
JP2022537987A5 (enExample)
JP6306075B2 (ja) 遺伝子発現と疼痛
US8962582B2 (en) PKR activation via hybridization chain reaction
JP2024531728A5 (enExample)
Englund et al. Synthesis of γ-substituted peptide nucleic acids: A new place to attach fluorophores without affecting DNA binding
JP2006515277A5 (enExample)
JP2006502694A5 (enExample)
JP2009532392A5 (enExample)
RU2005133711A (ru) Антисмысловые олигонуклеотиды (odn) к smad7 и их применение в области медицины
RU2007134212A (ru) Аптамерные терапевтические средства, применимые для лечения связанных с комплементом расстройств
JP2010533171A5 (enExample)
JP2006500958A5 (enExample)
JP2010512747A5 (enExample)
JP2024500036A5 (enExample)
WO2023041508A3 (en) Treatment of cardiovascular disease
Imbert et al. Lowering mutant huntingtin using tricyclo-DNA antisense oligonucleotides as a therapeutic approach for Huntington's disease
JP2006502243A5 (enExample)
WO2025157271A1 (zh) 一种抑制f11基因表达的核酸分子
CN118984717A (zh) Arnatar化合物和用于增强细胞摄取的方法
JPWO2005030960A1 (ja) ステイプル型オリゴヌクレオチドおよびそれからなる医薬
JP2025542331A (ja) 新規ｒｎａ治療薬及びその使用
CN101981188B (zh) 作为抗疟剂的rna适体的筛选
JP2026074094A (ja) Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド